Wilson’s disease is a genetic disorder caused by the loss of function of the ATP7B copper-binding protein that leads to impaired copper transport and excretion, which results in accumulation of free copper in the bloodstream that results in damage of liver, brain, and other organs. As Wilson’s disease is hard to differentiate from other serious hepatic or neurologic conditions such as jaundice and kidney failure, which results in less number of patient to be diagnosed than the actual prevalence of Wilson’s disease. Wilson’s disease is characterized by the degree of accumulation of free copper in liver and the brain. Whereas, the patients that suffer from Wilson’s disease can either be asymptomatic or can have one or more clinical symptoms which can vary in type and its severity that include liver disease, neurologic manifestations and psychiatric disturbances. The symptoms for Wilson’s disease may include abdominal pain, lack of appetite, fatigue, jaundice, problems with speech, swallowing or physical coordination, and uncontrolled movements or muscle stiffness. Wilson’s disease is suspected in the individuals of age 3 - 60 years, whereas the chance of child inheriting autosomal recessive mutation from both the parent by gene mutation is 25% or one in four ratio.
Wilson’s disease, also known as hepatolenticular degeneration or progressive lenticular degeneration, is a rare genetic disorder caused by copper poisoning in the body. In a healthy body, the liver filters the excess copper and releases it through urine. The liver of a person suffering from Wilson’s disease cannot perform this function. Wilson’s disease is diagnosed by blood tests through abnormalities in liver enzymes, copper levels in the blood, lower levels of ceruloplasmin, a protein that carries copper through the blood, a mutated gene or low blood sugar. Treatments of Wilson’s Disease include oral drugs containing zinc, d-penicillamine, Tetrathiomolybdate, and trientine or syprine.
Market Dynamics
Rising incidence of Wilson’s disease is due to increase in the population worldwide, as Wilson’s disease is a rare genetic disorder which, is expected to favor growth for Wilson’s disease treatment market around the globe. For instance, according to data published by National Library of Medicine, National Institute of Health, in May 2022, high incidence of Wilson’s disease is due to increased rate of consanguineous marriages. Both males and females are equally affected by Wilson’ disease.
Key features of the study:
- This report provides an in-depth analysis of the global Wilson’s disease treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global wilson’s disease treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Valeant Pharmaceuticals International, Inc., Noblepharma Co., Ltd., Wilson Therapeutics AB, Kadmon Holdings, Inc., Merck & Co., Inc., VHB Life Science Ltd., Teva Pharmaceuticals USA, Inc., and Tsumura & Co.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global Wilson’s disease treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Wilson’s disease treatment market
Detailed Segmentation:
- Global Wilson’s Disease Treatment Market, By Treatment Type:
- Medications
- D-Penicillamine
- Trientine
- Zinc
- Tetrathiomolybdate
- Others
- Global Wilson’s Disease Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Government Bodies
- Global Wilson’s Disease Treatment Market, By Region:
- North America
- By Treatment Type
- Medications
- D-Penicillamine
- Trientine
- Zinc
- Tetrathiomolybdate
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Government Bodies
- By Country
- Latin America
- By Treatment Type
- Medications
- D-Penicillamine
- Trientine
- Zinc
- Tetrathiomolybdate
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Government Bodies
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Treatment Type
- Medications
- D-Penicillamine
- Trientine
- Zinc
- Tetrathiomolybdate
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Government Bodies
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Treatment Type
- Medications
- D-Penicillamine
- Trientine
- Zinc
- Tetrathiomolybdate
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Government Bodies
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Treatment Type
- Medications
- D-Penicillamine
- Trientine
- Zinc
- Tetrathiomolybdate
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Government Bodies
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Treatment Type
- Medications
- D-Penicillamine
- Trientine
- Zinc
- Tetrathiomolybdate
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Government Bodies
- By Region/Country
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Valeant Pharmaceuticals International. Inc.
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Noblepharma Co., Ltd.
- Wilson Therapeutics AB
- Kadmon Holdings, Inc.
- Merck & Co.
- VHB Life Science Ltd.
- Teva Pharmaceuticals USA, Inc.
- Tsumura & Co.
“*” marked represents similar segmentation in other categories in the respective section
